TERESA FRAHM: Open Payments
NPI 1477530020 · SUPERIOR, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 34 payments from 9 companies in 2025. Trend: 2023 $660 · 2024 $513 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $202 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| Gilead Sciences, Inc. | 3 | $49 |
| Novo Nordisk Inc | 3 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Abbott Laboratories | 2 | $44 |
| Lundbeck LLC | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: VRAYLAR, REXULTI, SPRAVATO, Ozempic, CAPLYTA, FREESTYLE LIBRE 3, Auvelity, Epclusa.
Industry payments across NE — which companies pay providers there.
